Bright Minds Biosciences Inc. (NASDAQ:DRUG) has released its Management’s Discussion and Analysis (MD&A) for the third quarter ending June 30, 2024, showcasing a substantial reduction in net losses as the company advances its research and development (R&D) initiatives. Q3 2024 Fnancial Highlights ·  Net Loss Reduction: Bright Minds Biosciences reported a net loss of $1.8 million for the nine months ending June 30, 2024, significantly improved from the $5.8 million loss during the same period in 2023. This reduction is largely attributed to the timing of program starts and completions within their drug portfolio. ·  Cash Reserves: As of June 30, 2024, ...